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Imatinib mesylate (Gleevec
s or Glivec
s), a small molecule tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia,
has been said to herald the dawn of a new era of rationally designed, molecularly targeted oncotherapy. Lurking on the same new
horizon, however, is the age-old spectre of drug resistance. This review sets the intoxicating clinical perspective against the more
sobering laboratory evidence of such divergent mechanisms of imatinib resistance as gene amplification and stem cell quiescence.
Polychemotherapy has already been considered to combat resistance, but a more innovative, as yet unformulated, approach may be
advocated.
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Chronic myeloid leukaemia (CML), a myeloproliferative disorder
of haemopoietic stem cell origin, is characterised by the t(9;22)
reciprocal translocation giving rise to a shortened chromosome 22,
the so-called Philadelphia (Ph) chromosome. The resultant novel
fusion oncoprotein, BCR-ABL, has constitutive tyrosine kinase
activity and is considered causative in the disease. BCR-ABL
tyrosine kinase impinges on a number of downstream signalling
pathways resulting in the disruption of normal control of cellular
events such as proliferation, adhesion to bone marrow stroma and
apoptosis (reviewed in Sawyers, 1999). As BCR-ABL protein
expression is disease specific, and is present in 95% of CML cases,
it was a logical target for rationally designed therapy. Indeed,
signal transduction inhibitor 571 (STI571) emerged as a fastidious
BCR-ABL antagonist (Druker et al, 1996) inducing remarkable
haematological and cytogenetic remissions in interferon-intoler-
ant, -refractory or -resistant CML patients in the stable chronic
phase of the disease (Druker et al, 2001). STI571 is now marketed
as Glivec
s (Gleevec
s in USA); however, the current focus of many
laboratories is to elucidate mechanisms of resistance which may
emerge to the drug. In modelling such events, the hope would be
that clinicians could deliver a pre-emptive strike against what is
proving to be a tenacious and fascinating adversary in BCR-ABL.
DISEASE CHARACTERISTICS AND TREATMENT
CML is a triphasic disease, beginning with a relatively innocuous
chronic phase (CP), in which 50% of patients may be asympto-
matic, which lasts on average 4–5 years, progressing into
accelerated phase (AP, 6–18 months duration) and terminating
in fatal blast crisis (BC, 6 months) (Sawyers, 1999). As CML
progresses to BC, the malignant clone acquires additional genetic
mutations, including trisomy 8, isochromosome i (17q), trisomy 19
and double Ph, in the majority of patients and so the therapeutic
window, in terms of curative intent, is present only in the early
course of the disease. Moreover, mutations, deletions and
rearrangements of tumour-suppressor genes often arise.
In the 1950s, radiotherapy, splenectomy or chemotherapy were
the mainstay of treatment for CML. However, neither busulfan nor
hydroxyurea, antimetabolites still in use today, are more than
palliative as they fail to induce cytogenetic remission (CyR).
Interferon alpha (IFN-a), however, can induce a major CyR
(p35% Ph
+ metaphases) in up to 38% of patients, although its use
is associated with severe side effects, with the majority of patients
requiring dose reduction, or, indeed, cessation. IFN-a may be
coadministered with low-dose cytarabine, with better response
rates and survival being observed (Guilhot et al, 1997); however,
the combination tends to cause greater gastrointestinal tract and
mucosal toxicity. Another drug used in combination with IFN-a is
homoharringtonine (O’Brien et al, 2002), which is a plant alkaloid
with comparable activity. Recently, a pegylated form of IFN has
entered clinical trials (Talpaz et al, 2001). Pegylated IFN-a has
longer residence time in the body, hence a weekly, rather than
daily, subcutaneous dosing regimen. Of 27 CML patients intolerant
or resistant to IFN-a entered into a Phase I trial, pegylated IFN-a
induced a complete CyR in two of 19 patients with active disease.
Of the remaining eight patients already in complete haematological
remission (CHR), four achieved a complete, and three a partial,
CyR (Talpaz et al, 2001).
To date, only allogeneic bone marrow (allo-BMT) or peripheral
blood stem cell (PBSC) transplants offered any hope of a cure for
CML. Transplants cannot be offered to all patients, however, owing
to the lack of donor availability. Further, the age-related increased
risk of undergoing a transplant, along with greater likelihood of
concomitant disease such as diabetes or heart disease, mean that in
general this procedure is not performed on patients over the age of
55 years. Thus, as p210
BCR-ABL is present in 95% of CML patients,
is thought causative in the disease, and is constitutively active, a
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would offer the best hope for a nontransplant cure.
IMATINIB MESYLATE
One such molecularly targeted small molecule inhibitor is imatinib
mesylate (formerly STI571) a 2-phenylamino pyrimidine com-
pound (Figure 1A). The BCR-ABL tyrosine kinase requires
phosphate from ATP to phosphorylate its substrate molecules.
Imatinib occupies the ATP-binding site on BCR-ABL, thus
preventing substrate phosphorylation (Figure 1B). Imatinib is
not specific to BCR-ABL as it also interacts with the cell surface
receptor c-KIT in addition to regulating the kinase activity of the
platelet-derived growth factor receptor (PDGFR) (Druker et al,
1996). Indeed, imatinib has been found to inhibit phosphorylation
of c-KIT implicated in gastrointestinal stromal tumours and now
provides a new therapeutic option for this most common of all
gastrointestinal tract mesenchymal tumours (Demetri et al, 2002).
Imatinib has a low toxicity profile compared to many other
cytotoxic agents, indeed a maximum tolerated dose was not
reached in Phase I/II trials in CML (Druker et al, 2001). The most
common side effects were low-grade nausea, vomiting and other
gastrointestinal side effects including diarrhoea, reflux and taste
disturbance, as well as oedema (in particular periorbital), and skin
rashes. In a small proportion of patients, these toxicities
significantly affected their quality of life. For those patients in
BC taking imatinib at the higher dose of 800–1000mgday
1, more
toxic side effects (Grade 3–4 thrombocytopenia and neutropenia)
were evident. It should be remembered that pancytopenia is more
commonly seen in AP/BC CML reflecting the suppression of
normal haemopoiesis at this stage of the disease. Platelet and WBC
counts may take time to normalise on imatinib; however, if counts
do not recover adequately, these effects can be minimised by
imatinib dose reduction or temporary cessation of treatment.
Numerous clinical trials have been conducted using imatinib as
a treatment for CML (summarised in Table 1, Druker et al, 2001;
Guilhot et al, 2002; Kantarjian et al, 2002a–c; Sawyers et al, 2002;
Talpaz et al, 2002). The published results of these trials have been
very encouraging, and would argue for the need for commence-
ment of imatinib therapy following diagnosis to elicit durable
responses. Loss of imatinib-induced remissions is presumably
because of emerging drug resistance. BCR-ABL reactivation
can arise through gene amplification, resulting in higher levels of
BCR-ABL protein (Le Coutre et al, 2000; Mahon et al, 2000;
Weisberg and Griffin, 2000; Gorre et al, 2001). Alternatively, a gene
mutation in the ATP-binding pocket on BCR-ABL, which is the site
of action of imatinib, results in the inability of imatinib to
competitively bind out ATP (Gorre et al, 2001), although other
mechanisms of resistance may operate.
MECHANISMS OF RESISTANCE TO IMATINIB
IN Ph
+ CELLS
Gene amplification
It has been reported that in a proportion of CML BC-derived cell
lines, grown in vitro in the continuous presence of imatinib, BCR-
ABL gene amplification is observed (Le Coutre et al, 2000; Mahon
(i)
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Figure 1 (A) Molecular structure of imatinib. (B) Mode of action of
imatinib. (i) ATP binds to BCR/ABL and phosphorylates a tyrosine (Y)
residue of the substrate. The substrate can then bind to an effector
molecule triggering the cellular response. (ii) Imatinib binds to BCR/ABL
blocking the binding of ATP, thus the substrate tyrosine molecule is not
phosphorylated and cannot in turn bind and activate the effector molecule.
Table 1 Comparison of responses to imatinib therapy in CML
Study
Disease
phase
No. of
patients
Imatinib
(daily dose)
Complete
HR (%)
aMCyR
(%)
Complete
CyR (%)
bIRIS (imatinib) Guilhot et al (2002)
dc CP-Dx 553 400mg 94 83 68
IRIS (IFN-a) CP-Dx 553 5 MIUm
2 IFN + 20mgm
2
cytarabine
55 20 7
Druker et al (2001) CP 54 >300mg 98 54 13
Kantarjian et al (2002c) Late CP 454 400mg 95 76 41
Kantarjian et al (2002b) AP 200 400–600mg 80 45 24
Talpaz et al (2002) AP 181 400–600mg 53 48 17
Kantarjian et al (2002a) BC 75 300–1000mg 21 11 6
Sawyers et al (2002) BC 229 400–600mg 15 31 7
aMCyR=major cytogenetic response defined as complete (0% Ph
+) or partial (1–35% Ph
+).
bIRIS=International Randomized IFN vs. STI571 study.
cCP-Dx=newly diagnosed chronic phase.
dAnd personal communication from Dr Stephen O’Brien, Royal Victoria Infirmary, Newcastle.
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ABL protein has been identified in BCR-ABL transfected murine
Ba/F3 cells as well as in human LAMA84 and AR230 CML cell lines
(Mahon et al, 2000). The exact mechanism controlling this
enhanced BCR-ABL gene transcription and translation remains
uncertain, although it is not at the level of the BCR gene promoter.
If this were the case, the native BCR gene on the unaffected
chromosome 22 would also be expressed at increased levels in
resistant cells. In fact, BCR expression was much reduced in the
LAMA84-resistant cells as well as in the AR230-resistant cells
(Mahon et al, 2000). Since BCR protein has been proposed as a
negative regulator of BCR-ABL (Wu et al, 1999), low BCR levels
would compound the insensitivity to imatinib. Le Coutre et al
(2000) demonstrated BCR-ABL mRNA transcription to be 4.6 times
higher in their LAMA84-resistant cell line than in the parental
imatinib-sensitive cell line. Further, using FISH, the LAMA84R
cells were found to harbour X15 BCR-ABL gene copies per cell.
This study provides further compelling evidence implicating gene
amplification in resistance to imatinib.
To determine whether the gene amplification phenomenon
occurred in patients, clinical samples from CML patients who
relapsed after initially responding to imatinib, were analysed
(Gorre et al, 2001). In three of 11 samples, multiple copies of the
BCR-ABL gene were identified in interphase nuclei by FISH (two of
three were myeloid BC, the other lymphoid BC). Rather than an
overexpressed subclone attaining a relative growth advantage, it
has been hypothesised that imatinib itself may have initiated the
BCR-ABL gene amplification. For example, in one of these three
patients who received alternative treatment for relapsed leukaemia,
it was no longer possible, 4 weeks after cessation of imatinib
therapy, to detect BCR-ABL gene amplification. While these are
interesting observations, the number of patients in this cohort was
small, hence the findings may not be truly representative of all
CML BC patients, nor of CML which progresses from CP.
Interestingly, Tipping et al could restore sensitivity of a
LAMA84-resistant cell line to imatinib after 2 months withdrawal
from continuous exposure to the drug. It was surmised that a
subgroup of resistant patients may benefit from interruption,
followed by resumption at a later date, of therapy (Tipping et al,
2001).
Mutations in ATP-binding pocket
Another mechanism underlying imatinib resistance is point
mutations in the BCR-ABL gene altering the conformation of the
ATP-binding pocket such that imatinib no longer has affinity.
Analysis of the 579-base pair region, which gives rise to the ATP-
binding pocket and the activation loop of the kinase domain on
BCR-ABL, revealed in six of nine patients a C-T change at
nucleotide 944 (Gorre et al, 2001). The latter transition corre-
sponds to an isoleucine substitution for threonine at position 315
(T315I) in the ATP-binding pocket, which does not inhibit ATP
binding. Such a change, however, would inhibit drug binding
owing to steric hindrance and loss of critical hydrogen bond
formation. Von Bubnoff et al (2002) have analysed a group of eight
patients with Ph
+ leukaemias, of which two were CML in BC or AP/
BC. This group also detected the T315I in one patient, as well as
reporting four novel point mutations all located within the drug-
binding pocket on BCR-ABL. Branford et al (2002) found that nine
of 12 CML patients resistant to imatinib had a mutation within the
ATP-binding region of BCR-ABL. A range of mutations was
observed, including T315I. Roumiantsev et al (2002) found that the
Y253F mutation in the Abl kinase domain conferred intermediate
resistance to imatinib, both in vitro and in vivo, relative to the
T315I mutation.
However, the clinical significance of the T315I mutation to
imatinib resistance was questioned by the studies of Barthe et al
(2001) and Hochhaus et al (2001). The former group found no
C-T transition, and only one G-A mutation in their analysis of
12 patients, while the latter study identified only one A-T
mutation in a cohort of 32 patients. Mahon et al (2000) studied the
Ph
+ imatinib resistant-cell lines K562-R and AR230-R, but found
no mutations in the ATP binding pocket. Similarly, Le Coutre et al
(2000) identified no mutations in their LAMA84R cell line.
It should be borne in mind, however, the likely range of mutations
that will be observed in populations of different genetic back-
ground (Barthe et al, 2001).
While there is now some consensus regarding the particular
mutations detected, the reported incidence of each mutation in
patients is variable. The most recent data are more relevant to the
clinic since the cells used in these analyses were procured from
patients, compared to previous studies employing cell lines (Le
Coutre et al, 2000; Mahon et al, 2000).
Alpha-1-acid glycoprotein (AGP)
Alpha-1-acid glycoprotein (AGP), an extensively glycosylated
plasma protein and known binder of drugs (Fournier et al,
2000), changes both quantitatively and qualitatively (in terms of
glycosylation) in response to inflammation and disease, such as
cancer. In a recent study by Jrgensen et al (2002b) investigating a
possible link between decreased imatinib efficacy and AGP-drug
binding, AGP levels were found to be significantly raised in CML
patients at all stages of disease compared to normal controls.
Normal AGP, even at up to seven times the normal population
average concentration of 0.77mgml
1 (Blain et al, 1985), had no
influence on the effect of imatinib on the Ph
+ K562 BC cell line.
AGP isolated from individual CML patients did not confer any loss
of function of imatinib in the assay. Further, in a direct binding
assay whereby any AGP-imatinib interaction is detected as
fluorescence quenching, imatinib did not bind normal AGP at
clinically relevant concentrations of the drug (5mM)( J rgensen
et al, 2002c). Gorre et al (2001) clearly demonstrated cell intrinsic
mechanisms of resistance to Glivec
s whereby cells taken from
relapsing patients showed reduced sensitivity to the drug with
evidence of acquired molecular changes such as gene mutation or
amplification.
However, Gambacorti-Passerini et al, 2000 (Le Coutre et al,
2002) argue for a role for AGP-imatinib binding as a mechanism of
drug resistance. To overcome their observed binding of normal
AGP (which by definition will have a different glycosylation
pattern from CML-derived AGP and be of limited clinical
relevance) to imatinib, it was suggested using clindamycin or
erythromycin concomitantly, since the antibiotics purportedly
compete with imatinib for AGP-binding sites. Larghero et al (2001)
found whole sera from BC CML patients, comprising AGP up
to 3mgml
1 and numerous other drug-binding candidates, to
prevent K562 cell death in vitro when incubated with up to 10mM
imatinib. Reportedly, erythromycin addition reversed the effect of
AGP. The fact that all the patients in BC failed to respond to
imatinib was attributed to the high levels of AGP, while those in
the early phases of the disease with lower AGP levels responded to
the drug. It was noted in a cohort of 39 patients (Le Coutre et al,
2002) that AGP levels were related to rate of response to imatinib;
however, the effectiveness of the drug was unaltered by AGP
concentration. None of the studies supporting AGP-imatinib
binding convincingly distinguish ‘cause and effect’. It has not
been proven definitively that an elevated AGP plasma concentra-
tion is the direct cause of imatinib resistance as opposed to simply
being a surrogate marker for disease progression.
Quiescent stem cells
To further add to the mechanisms of resistance to imatinib, results
from a study by Graham et al (2002) stress the importance of
quiescent Ph
+ stem cells. These cells, which can be isolated from all
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stem cell marker, CD34, and are part of the leukaemic clone being
BCR-ABL
+ by RT-PCR and Ph
+ by FISH. While the cells are out of
cycle, they have been found to be resistant to the anti-leukaemic
effects of imatinib. This would be problematic in patients in whom
a molecular remission has been induced by imatinib, which is then
discontinued. If quiescent Ph
+ stem cells persist, which retain the
potential to spontaneously enter a proliferating state, the
leukaemic clone would then be re-established and CML would
recur. In this scenario, continued treatment, even in the minimal
residual disease scenario, would be required to target newly
emerging leukaemic cells. From a pharmacoeconomic point of
view, however, it would be preferable to completely eradicate the
Ph
+ clone enabling discontinuation of therapy. Furthermore, a
maintenance strategy runs the risk of forcing the emergence of
truly resistant clones, that is, resistant through additional
mechanisms other than by virtue of their quiescence.
Multidrug resistance protein
Resistance of certain cancer cells to drugs such as anthracycline or
vinca alkaloids can be caused by an increase in the expression of
the multidrug resistance-1 (MDR-1) gene (Brinkmann et al, 2001).
This gene encodes P-glycoprotein (Pgp), a member of the ATP-
binding cassette (ABC) protein family, which function to remove
toxic molecules from cells. The imatinib-resistant leukaemic cell
line LAMA84R was observed to express Pgp at higher levels than
the sensitive cell line (Mahon et al, 2000). Furthermore, cells taken
from patients in BC were found to express Pgp only when the
patients had relapsed, and not when they were responding to
therapy (Kuwazuru et al, 1990). Recent results have indicated that
there is a correlation between MDR-1 gene expression and relapse
of patients taking imatinib (Deininger et al, 2001). Higher levels of
MDR-1 are observed at the time of relapse compared to levels pre-
therapy. While the leukaemic cells may themselves have increased
numbers of such xenobiotic transporters, Pgp is also located on the
epithelial cells of the gastrointestinal tract. This may decrease
upper gastrointestinal absorption of orally administered drugs,
such as imatinib, resulting in yet another potential method of
resistance. Furthermore, single nucleotide polymorphisms in the
MDR-1 gene may result in altered affinity for cytotoxic drugs,
possibly explaining imatinib insensitivity in some patients
(Brinkmann et al, 2001).
CONCLUSIONS AND FUTURE PERSPECTIVES
In summary, it is becoming apparent that a variety of mechanisms
may result in resistance to imatinib, and indeed some patients may
exhibit more than one mode of resistance. In order to combat this,
combinatorial therapies against proliferating Ph
+ cells, and
attempts to eradicate quiescent leukaemic stem cells (Jrgensen
et al, 2002a), will be of great importance in treatment of CML.
Combinations of imatinib with IFN-a or vincristine (Kano et al,
2001); daunorubicin or cytarabine arabinoside (Thiesing et al,
2000); or more novel compounds such as the Janus kinase 2 (JAK2)
inhibitor AG490 (Sun et al, 2001); or farnesyl transferase inhibitors
(FTI) (Hoover et al, 2002) including SCH66336, may synergistically
enhance the effect of imatinib alone. It has yet to be shown if
improved survival rates may be achieved by prescribing imatinib
along with additional agents in relapsing CML patients. However,
pre-emptive combinatorial therapies may prove to avert, or at least
delay resistance to imatinib therapy. In addition to selecting a
synergistic partner for imatinib, dose scheduling must also be
considered as it has also been reported that imatinib sensitivity
may be restored in certain drug-resistant CML cells (Tipping et al,
2001). It appears to be beneficial to stop treatment with imatinib
temporarily and resume at a later date, at which point the CML
cells appear sensitive to the drug once again. This phenomenon
may be explained by the lack of selection pressure for BCR-ABL
imposed on CML cells by imatinib.
Clearly, there are still advances to be made towards the
nontransplant cure of CML, but given the unprecedented rapid
regulatory approval given to imatinib by the Food and Drug
Administration (FDA), further developments of safe and effective,
rationally designed drugs should be available to patients quicker
than ever before.
ACKNOWLEDGEMENTS
SCP is a recipient of a Caledonian Research Foundation PhD
Scholarship, and HGJ is supported by a Kay Kendall Leukaemia
Fund Personal Fellowship. We gratefully acknowledge Dr Moira
Elliott, Cancer Research UK Formulation Unit, for assistance in the
preparation of this manuscript.
REFERENCES
Barthe C, Cony-Makhoul P, Melo J, Mahon J (2001) Roots of clinical
resistance to STI-571 cancer therapy. Science 293: 2163
Blain PG, Mucklow JC, Rawlins MD, Roberts DF, Routledge PA, Shand DG
(1985) Determinants of plasma alpha-1-acid glycoprotein (AAG)
concentrations in health. Br J Clin Pharmacol 20: 500–502
Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R,
Lynch K, Hughes T (2002) High frequency of point mutations clustered
within the adenosine triphosphate-binding region of BCR/ABL in
patients with chronic myeloid leukemia or Ph-positive acute lympho-
blastic leukemia who develop imatinib (STI571) resistance. Blood 99:
3472–3475
Brinkmann U, Roots I, Eichelbaum M (2001) Pharmacogenetics of the
human drug-transporter gene MDR1: impact of polymorphisms on
pharmacotherapy. Drug Discov Today 6: 835–839
Deininger M, Leiblein S, Keohler T, Guenther R, Kovacs I, Ben-Am M, Al-
Ali H, Reiner K, Niederwieser D (2001) In vivo resistance to Glivec is not
consistantly associated with resistance in vitro but may be related to
increased MDR-1 expression. Blood 98: 176b
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B,
Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA,
Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic
S, Druker BJ, Corless C, Fletcher CDM, Joensuu H (2002) Efficacy and
safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
N Eng J Med 347: 472–480
Druker BJ, Talpaz M, Resta DJ, Bin Peng RN, Buchdunger E, Ford JM,
Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase
in chronic myeloid leukemia. N Eng J Med 344: 1031–1037
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S,
Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the
Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:
561–566
Fournier T, Medjoubi NN, Porquet D (2000) Alpha-1-acid glycoprotein.
Biochim Biophys Acta 1482: 157–171
Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris
L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E,
Corneo G, Formelli F, D’Incalci M (2000) Role of alpha1 acid
glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic
cells to the abl inhibitor STI571. J Nat Cancer Inst 92: 1641–1650
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers
CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-
ABL gene mutation or amplification. Science 293: 876–880
Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L,
Holyoake TL (2002) Primitive quiescent Philadelphia-positive stem cells
Resisting imatinib in CML
SC Paterson et al
986
British Journal of Cancer (2003) 88(7), 983–987 & 2003 Cancer Research UKfrom patients with chronic myeloid leukemia are insensitive to STI571 in
vitro. Blood 99: 319–325
Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J, Maloisel F,
Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall J, Tanzer J
(1997) Interferon alfa-2b combined with cytarabine versus interferon
alone in chronic myelogenous leukemia. French Chronic Myeloid
Leukemia Study Group. N Engl J Med 337: 223–229
Guilhot F, O’Brien SG, Druker B, Larson RA (2002) Imatinib (STI571,
Glivec) as initial therapy for patients with CML: results of a randomized
phase III study versus interferon (IFN) cytarabine. Hematol J 3: 181
Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, Cross N,
Linkesch W, Druker B, Hehlmann R (2001) Roots of clinical resistance to
STI-571 cancer therapy. Science 293: 2163a
Hoover R, Mahon F, Melo J, Daley G (2002) Overcoming STI571 resistance
with the farnesyl transferase inhibitor SCH66336. Blood 100: 1068–1071
Jrgensen H, Allan E, Graham S, Richmond L, Godden J, Holyoake T
(2002a) Will drug combinations effectively eradicate quiescent leukaemic
stem cells in chronic myeloid leukaemia. Exp Hematol 30: 73
Jrgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD
(2002b) Alpha-1-acid glycoprotein expressed in the plasma of chronic
myeloid leukaemia patients does not mediate significant in vitro
resistance to STI571 (Glivec). Blood 99: 713–715
Jrgensen HG, Elliott MA, Paterson S, Holyoake TL, Smith KD (2002c)
Further observations on the debated ability of AGP to bind imatinib.
Blood 100: 368–369
Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y
(2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571
in combination with commonly used antileukemic agents. Blood 97:
1999–2007
Kantarjian H, Cortes J, O’Brien S, Giles F, Albitar M, Rios M, Shan J, Faderl
S, Garcia-Manero G, Thomas D, Resta D, Talpaz M (2002a) Imatinib
mesylate (STI571) therapy for Philadelphia chromosome-positive
chronic myelogenous leukemia in blast phase. Blood 99: 3547–3553
Kantarjian H, O’Brien S, Cortes J, Smith TL, Rios M, Shan J, Yang Y, Giles
F, Thomas D, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa J,
Kornblau S, Keating M, Resta D, Capdeville R, Talpaz M (2002b)
Treatment of philadelphia chromosome-positive, accelerated-phase
chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res
8: 2167–2176
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-
Passerini C, Niedwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M,
Druker B, Goldman J, O’Brien S, Russell N, Fuscher T, Ottman O, Cony-
Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M,
Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D,
Baccarini M, Morra E (2002c) Hematologic and cytogenetic responses to
imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:
645–652
Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K,
Utsunomiya A, Arima T, Akiyama S (1990) Expression of the multidrug
transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in
blast crisis. Br J Haematol 74: 24–29
Larghero J, Mahon F, Madelaine-Chambrin I, Raffoux E, Faure P, Berthaud
P, Taksin A, Bastie J, Dombret H, Degos L, Chomienne C, Rousselot P
(2001) Elevated levels of plasma protein alpha 1 acid glycoprotein in
chronic myelogenous leukemia in blast crisis mediate pharmacological
resistance to Gleevec (STI571, imatinib) in vitro and are associated with
primary resistance in vivo. Blood 98: 616a
Le Coutre P, Kreuzer K, Na I, Lupberger J, Holdoff M, Appelt C, Schwarz M,
Muller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G,
Schmidt C (2002) Determination of alpha-1 acid glycoprotein in patients
with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy
with STI571. Blood Cells Mol Dis 28: 75–85
Le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G,
Marchesis E, Supino R, Gambacorti-Passerini C (2000) Induction of
resistance to the Abelson inhibitor STI571 in human leukemic cells
through gene amplification. Blood 95: 1758–1766
Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman
JM, Melo JV (2000) Selection and characterization of BCR-ABL
positive cell lines with differential sensitivity to the tyrosine kinase
inhibitor STI571: diverse mechanisms of resistance. Blood 96:
1070–1079
O’Brien S, Talpaz M, Cortes J, Shan J, Giles F, Faderl S, Thomas D, Garcia-
Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo
A, Keating M, Kantarjian H (2002) Simultaneous homoharringtonine and
interferon-alpha in the treatment of patients with chronic-phase chronic
myelogenous leukemia. Cancer 94: 2024–2032
Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van
Etten RA (2002) Clinical resistance to the kinase inhibitor STI-571 in
chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase
domain P-loop. Proc Nat Acad Sci USA 99: 10700–10705
Sawyers C, Hochhaus A, Feldman E, Goldman J, Miller C, Ottmann O,
Schiffer C, Talpaz M, Guilhot F, Deininger M, Fischer T, O’Brien S, Stone
R, Gambacorti-Passerini C, Russell N, Reiffers J, Shea T, Chapuis B,
Coutre S, Tura S, Morra E, Larson R, Saven A, Peschel C, Gratwohl A,
Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette R, Druker B
(2002) Imatinib induces hematologic and cytogenetic responses in
patients with chronic myelogenous leukemia in myeloid blast crisis:
results of a phase II study. Blood, 99: 3530–3539
Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:
1330–1340
Sun X, Layton JE, Elefanty A, Lieschke GJ (2001) Comparison of effects of
the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-
expressing cells, demonstrating synergy between AG490 and STI571.
Blood 97: 2008–2015
Talpaz M, O’Brien S, Rose E, Gupta S, Shan J, Cortes J, Giles F, Faderl S,
Kantarjian H (2001) Phase 1 study of polyethylene glycol formulation of
interferon alpha-2B (Schering 54031) in Philadelphia chromosome-
positive chronic myelogenous leukemia. Blood 98: 1708–1713
Talpaz M, Silver R, Druker B, Goldman J, Gambacorti-Passerini C, Guilhot
F, Schiffer C, Fischer T, Deininger M, Lennard A, Hochhaus A, Ottmann
O, Gratwohl A, Baccarini M, Stone R, Tura S, Mahon F, Fernandes-Reese
S, Gathmann I, Capdeville R, Kantarjian H, Sawyers C (2002) Imatinib
induces durable hematologic and cytogenetic responses in patients with
accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 99: 1928–1937
Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ (2000) Efficacy
of STI571, an abl tyrosine kinase inhibitor, in conjunction with
other antileukemic agents against bcr-abl-positive cells. Blood 96:
3195–3199
Tipping A, Mahon F, Lagarde V, Goldman J, Melo J (2001) Restoration of
sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells.
Blood 98: 3864–3867
von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCR-ABL gene
mutations in relation to clinical resistance of Philadelphia-chromosome-
positive leukaemia to STI571: a prospective study. Lancet 359: 487–491
Weisberg E, Griffin JD (2000) Mechanism of resistance to the ABL tyrosine
kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell
lines. Blood 95: 3498–3505
Wu Y, Ma G, Lu D, Lin F, Xu HJ, Liu J, Arlinghaus, RB (1999) Bcr: a
negative regulator of the Bcr-Abl oncoprotein. Oncogene 18: 4416–4424
Resisting imatinib in CML
SC Paterson et al
987
British Journal of Cancer (2003) 88(7), 983–987 & 2003 Cancer Research UK